-
Company Insights
Innovation and Patenting activity of Caribou Biosciences Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Caribou Biosciences Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Primary Mediastinal B-Cell Lymphoma Drug Details: CB-010 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Mantle Cell Lymphoma Drug Details: CB-010 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Follicular Lymphoma Drug Details: CB-010 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in Diffuse Large B-Cell Lymphoma Drug Details: CB-010 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in B-Cell Non-Hodgkin Lymphoma Drug Details: CB-010 is under development...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewMarginal Zone B-cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It's divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include...
-
Product Insights
parque Solar Mesetas
parque Solar Mesetas is a solar PV project located in Huila, Colombia. The project is owned and being developed by Desarrollos Energeticos Del Caribe SAS. The project is expected to come online in 2026. Empower your strategies with our parque Solar Mesetas report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...